NovoTTF-100A + TCCC + bevacizumab

This is a combination therapy consisting of three components: 1. **NovoTTF-100A** (Optune): A portable, non-invasive medical device that delivers Tumor Treating Fields (TTFields)—low-intensity, intermediate-frequency alternating electric fields—via transducer arrays applied to the scalp. These fields disrupt mitosis in dividing tumor cells, leading to cell death and inhibition of tumor growth. It is FDA-approved for recurrent glioblastoma multiforme (GBM) and has demonstrated efficacy comparable to chemotherapy with fewer systemic side effects[2][3][7]. 2. **TCCC**: This abbreviation typically refers to a multi-agent chemotherapy regimen; however, the specific agents included under "TCCC" are not defined in the provided sources or standard oncology references. In some contexts, it may refer to combinations such as temozolomide-based regimens or other platinum-based chemotherapies used for brain tumors. 3. **Bevacizumab** (Avastin): A recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby restricting blood supply to tumors. This combination aims at multimodal management of aggressive brain tumors like glioblastoma by combining physical disruption of cancer cell division with cytotoxic chemotherapy and antiangiogenic therapy.

Brand names

OptuneAvastin

Other names

NovoTTF System + TCCC + Avastin